NVO ▲ +1.8% - Novo Nordisk A/S $NVO Novo Nordisk: CagriSema Shows 25.4% Average Weight Loss Among Early Responders in Phase 3 Analysis ? • Weight Loss: 67.8% of patients were early responders (≥5% weight loss by week 8), achieving 25.4% average weight loss at week 68 versus 17.8% among delayed responders. • Physical Function: 73.1% reported meaningful improvement versus 49.1% with placebo. • Psychosocial Function: 69.0% reported meaningful improvement versus 42.1% with placebo. • Regulatory Outlook: FDA decision on CagriSema expected in Q4 2026. Results are from exploratory post hoc analyses, not a new primary trial readout. 15-NOV-2026 03:18 PM ET